Size matters: the effects of varying zinc oxide nanoparticle sizes on human cytochrome P450 enzyme activity and gene expression
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Computational Drug Discovery Methods · Drug Transport and Resistance Mechanisms · Pharmacogenetics and Drug Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Åslund AKO, Pottier A, Schiffelers R, Ceccaldi A, Schmid R (2020) Delivering the power of nanomedicine to patients today. J Control Release 326:164–17110.1016/j.jconrel.2020.07.007 ↗
2. Kargozar S, Mozafari M (2018) Nanotechnology and nanomedicine: start small, think big. Mater Today: Proc 5:15492–15500
3. Weissig V, Elbayoumi T, Flühmann B, Barton A (2021) The growing field of nanomedicine and its relevance to pharmacy curricula. Am J Pharm Educ 85:833110.5688/ajpe8331 ↗
4. Abdel-Mageed HM, AbuelEzz NZ, Radwan RA, Mohamed SA (2021) Nanoparticles in nanomedicine: a comprehensive updated review on current status, challenges and emerging opportunities. J Microencapsul 38:414–43610.1080/02652048.2021.1942275 ↗
5. Albalawi F, Hussein MZ, Fakurazi S, Masarudin MJ (2021) Engineered nanomaterials: the challenges and opportunities for nanomedicines. Int J Nanomedicine 16:161–18410.2147/IJN.S288236 ↗
6. Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z (2022) Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharmaceutica Sinica B 12:3028–304810.1016/j.apsb.2022.02.025 ↗
7. Metwally A, Abdel-Hady A-NAA, Ebnalwaled K, Morad SAF, Soliman AA (2020) Wound-healing activity of green and chemical zinc oxide nanoparticles (ZnO-NPs) gels in equine wounds: a clinical study. SVU-Int J Vet Sci 3:66–79
8. Anjum S, Hashim M, Malik SA, Khan M, Lorenzo JM, Abbasi BH, Hano C (2021) Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment. Cancers 13:457010.3390/cancers13184570 ↗
9. Cai X, Luo Y, Zhang W, Du D, Lin Y (2016) pH-sensitive ZnO quantum dots–doxorubicin nanoparticles for lung cancer targeted drug delivery. ACS Appl Mater Interfaces 8:22442–2245010.1021/acsami.6b04933 ↗
10. Sadhukhan P, Kundu M, Chatterjee S, Ghosh N, Manna P, Das J, Sil PC (2019) Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy. Mater Sci Eng, C 100:129–14010.1016/j.msec.2019.02.096 ↗
11. Vaghari-Tabari M, Jafari-Gharabaghlou D, Mohammadi M, Hashemzadeh MS (2023) Zinc oxide nanoparticles and cancer chemotherapy: helpful tools for enhancing chemo-sensitivity and reducing side effects? Biol Trace Elem Res. https://doi.org/10.1007/s12011-023-03803-z10.1007/s12011-023-03803-z ↗
12. Stepankova H, Swiatkowski M, Kruszynski R et al (2021) The anti-proliferative activity of coordination compound-based ZnO nanoparticles as a promising agent against triple negative breast cancer cells. Int J Nanomedicine 16:4431–444910.2147/IJN.S304902 ↗
13. Tanino R, Amano Y, Tong X, Sun R, Tsubata Y, Harada M, Fujita Y, Isobe T (2020) Anticancer activity of ZnO nanoparticles against human small-cell lung cancer in an orthotopic mouse model. Mol Cancer Ther 19:502–51210.1158/1535-7163.MCT-19-0018 ↗
14. Wang Y, Zhang Y, Guo Y, Lu J, Veeraraghavan VP, Mohan SK, Wang C, Yu X (2019) Synthesis of zinc oxide nanoparticles from Marsdenia tenacissima inhibits the cell proliferation and induces apoptosis in laryngeal cancer cells (Hep-2). J Photochem Photobiol, B 201:11162410.1016/j.jphotobiol.2019.111624 ↗
15. Majeed S, Danish M, Ismail MHB, Ansari MT, Ibrahim MNM (2019) Anticancer and apoptotic activity of biologically synthesized zinc oxide nanoparticles against human colon cancer HCT-116 cell line- in vitro study. Sustain Chem Pharm 14:10017910.1016/j.scp.2019.100179 ↗
16. Ancona A, Dumontel B, Garino N, Demarco B, Chatzitheodoridou D, Fazzini W, Engelke H, Cauda V (2018) Lipid-coated zinc oxide nanoparticles as innovative ROS-generators for photodynamic therapy in cancer cells. Nanomaterials 8:14310.3390/nano8030143 ↗
17. Berehu HM, S A, Khan MI, Chakraborty R, Lavudi K, Penchalaneni J, Mohapatra B, Mishra A, Patnaik S (2021) Cytotoxic potential of biogenic zinc oxide nanoparticles synthesized from Swertia chirayita leaf extract on colorectal cancer cells. Front Bioeng Biotech 9: https://doi.org/10.3389/fbioe.2021.78852710.3389/fbioe.2021.788527 ↗
18. Mohammadi Shivyari A, Tafvizi F, Noorbazargan H (2022) Anti-cancer effects of biosynthesized zinc oxide nanoparticles using Artemisia scoparia in Huh-7 liver cancer cells. Inorg Nano-Metal Chem 52:375–386
19. Wang J, Lee JS, Kim D, Zhu L (2017) Exploration of zinc oxide nanoparticles as a multitarget and multifunctional anticancer nanomedicine. ACS Appl Mater Interfaces 9:39971–3998410.1021/acsami.7b11219 ↗
20. National Archives and Records Administration, Office of the Federal Register (2024) Substances generally recognized as safe. Food and drugs. Title 21. United States: National Archives and Records Administration. Retrieved from https://www.govinfo.gov/content/pkg/CFR-2024-title21-vol3/pdf/CFR-2024-title21-vol3.pdf
21. Nagarajan M, Maadurshni GB, Tharani GK, Udhayakumar I, Kumar G, Mani KP, Sivasubramanian J, Manivannan J (2022) Exposure to zinc oxide nanoparticles (ZnO-NPs) induces cardiovascular toxicity and exacerbates pathogenesis – role of oxidative stress and MAPK signaling. Chem Biol Interact 351:10971910.1016/j.cbi.2021.109719 ↗
22. Jin M, Li N, Sheng W, Ji X, Liang X, Kong B, Yin P, Li Y, Zhang X, Liu K (2021) Toxicity of different zinc oxide nanomaterials and dose-dependent onset and development of Parkinson’s disease-like symptoms induced by zinc oxide nanorods. Environ Int 146:10617910.1016/j.envint.2020.106179 ↗
23. Du J, Tang J, Xu S, Ge J, Dong Y, Li H, Jin M (2020) ZnO nanoparticles: recent advances in ecotoxicity and risk assessment. Drug Chem Toxicol 43:322–33310.1080/01480545.2018.1508218 ↗
24. Chong CL, Fang CM, Pung SY, Ong CE, Pung YF, Kong C, Pan Y (2021) Current updates on the in vivo assessment of zinc oxide nanoparticles toxicity using animal models. BioNanoSci 11:590–62010.1007/s12668-021-00845-2 ↗
25. Zaiter T, Cornu R, El Basset W, Martin H, Diab M, Béduneau A (2022) Toxicity assessment of nanoparticles in contact with the skin. J Nanopart Res 24:14910.1007/s11051-022-05523-2 ↗
26. Ahadian S, Radisic M (2017) 12 - Nanotoxicity. In: Razavi M, Thakor A (eds) Nanobiomaterials Science. Woodhead Publishing, Development and Evaluation, pp 233–248
27. Gupta D, Yadav P, Garg D, Gupta TK (2021) Pathways of nanotoxicity: modes of detection, impact, and challenges. Front Mater Sci 15:512–54210.1007/s11706-021-0570-8 ↗
28. Morris AS, Salem AK (2017) Nanotoxicity. Nanomed Inflamm Dis. https://doi.org/10.1201/9781315152356-410.1201/9781315152356-4 ↗
29. Teng C, Jia J, Wang Z, Sharma VK, Yan B (2019) Size-dependent maternal-fetal transfer and fetal developmental toxicity of ZnO nanoparticles after oral exposures in pregnant mice. Ecotoxicol Environ Saf 182:10943910.1016/j.ecoenv.2019.109439 ↗
30. Lin Y-F, Chiu I-J, Cheng F-Y, Lee Y-H, Wang Y-J, Hsu Y-H, Chiu H-W (2015) The role of hypoxia-inducible factor-1α in zinc oxide nanoparticle-induced nephrotoxicity in vitro and in vivo. Part Fibre Toxicol 13:5210.1186/s12989-016-0163-3 ↗
31. Guo Z, Luo Y, Zhang P et al (2020) Deciphering the particle specific effects on metabolism in rat liver and plasma from ZnO nanoparticles versus ionic Zn exposure. Environ Int 136:10543710.1016/j.envint.2019.105437 ↗
32. Özturk N, Ceylan H, Demir Y (2024) The hepatoprotective potential of tannic acid against doxorubicin-induced hepatotoxicity: insights into its antioxidative, anti-inflammatory, and antiapoptotic mechanisms. J Biochem Mol Toxicol 38:e2379810.1002/jbt.23798 ↗
33. Manikandan P, Nagini S (2018) Cytochrome P450 structure, function and clinical significance: a review. CDT. https://doi.org/10.2174/138945011866617012514455710.2174/1389450118666170125144557 ↗
34. Slaughter RL, Edwards DJ (1995) Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29:619–62410.1177/106002809502900612 ↗
35. Feltrin C, Oliveira Simões CM (2019) Reviewing the mechanisms of natural product-drug interactions involving efflux transporters and metabolic enzymes. Chem Biol Interact 314:10882510.1016/j.cbi.2019.108825 ↗
36. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–14110.1016/j.pharmthera.2012.12.007 ↗
37. Türkeş C, Kesebir AÖ, Demir Y, Küfrevioğlu Öİ, Beydemir Ş (2021) Calcium channel blockers: the effect of glutathione S-transferase enzyme activity and molecular docking studies. ChemistrySelect 6:11137–1114310.1002/slct.202103100 ↗
38. Türkeş C (2019) A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors†. J Pharm Pharmacol 71:1553–156410.1111/jphp.13141 ↗
39. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–5710.2165/00003088-200038010-00003 ↗
40. Vega AJ, Smith C, Matejowsky HG, Thornhill KJ, Borne GE, Mosieri CN, Shekoohi S, Cornett EM, Kaye AD (2023) Warfarin and antibiotics: drug interactions and clinical considerations. Life 13:166110.3390/life13081661 ↗
41. Alpert JE (2008) CHAPTER 50 - Drug-drug interactions in psychopharmacology. In: Stern TA, Rosenbaum JF, Fava M, Biederman J, Rauch SL (eds) Massachusetts General Hospital Comprehensive Clinical Psychiatry. Mosby, Philadelphia, pp 687–70410.1016/B978-0-323-04743-2.50052-4 ↗
42. Fleming I (2008) Vascular cytochrome P450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 18:20–2510.1016/j.tcm.2007.11.002 ↗
43. Daniel WA, Bromek E, Danek PJ, Haduch A (2022) The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions. Biochem Pharmacol 199:11500610.1016/j.bcp.2022.115006 ↗
44. Jarrar Y, Al-Doaiss A, Alfaifi M, Shati A, Al-Kahtani M, Jarrar B (2020) The influence of five metallic nanoparticles on the expression of major drug-metabolizing enzyme genes with correlation of inflammation in mouse livers. Environ Toxicol Pharmacol 80:10344910.1016/j.etap.2020.103449 ↗
45. Al-Hamadani MYI, Alzahrani AM, Yousef MI, Kamel MA, El-Sayed WM (2020) Gold nanoparticles perturb drug-metabolizing enzymes and antioxidants in the livers of male rats: potential impact on drug interactions. Int J Nanomedicine 15:5005–501610.2147/IJN.S248194 ↗
46. Tang H, Xu M, Luo J, Zhao L, Ye G, Shi F, Lv C, Chen H, Wang Y, Li Y (2019) Liver toxicity assessments in rats following sub-chronic oral exposure to copper nanoparticles. Environ Sci Eur 31:3010.1186/s12302-019-0214-0 ↗
47. Wang Y, Tang H, Xu M, Luo J, Zhao L, Shi F, Ye G, Lv C, Li Y (2019) Effect of copper nanoparticles on brain cytochrome P450 enzymes in rats. Mol Med Rep 20:771–778
48. Zhou S, Li X, Zhu M et al (2020) Hepatic impacts of gold nanoparticles with different surface coatings as revealed by assessing the hepatic drug-metabolizing enzyme and lipid homeostasis in mice. NanoImpact 20:10025910.1016/j.impact.2020.100259 ↗
49. Xu M, Tang H, Zhou X et al (2018) Effects and mechanisms of sub-chronic exposure to copper nanoparticles on renal cytochrome P450 enzymes in rats. Environ Toxicol Pharmacol 63:135–14610.1016/j.etap.2018.08.004 ↗
50. Ladda MA, Goralski KB (2016) The effects of CKD on cytochrome P450–mediated drug metabolism. Adv Chronic Kidney Dis 23:67–7510.1053/j.ackd.2015.10.002 ↗
51. Demir Y (2020) Naphthoquinones, benzoquinones, and anthraquinones: Molecular docking, ADME and inhibition studies on human serum paraoxonase-1 associated with cardiovascular diseases. Drug Dev Res 81:628–63610.1002/ddr.21667 ↗
52. McDonnell AM, Dang CH (2013) Basic review of the cytochrome P450 system. J Adv Pract Oncol 4:263–268
53. Lee J, Beers JL, Geffert RM, Jackson KD (2024) A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment. Biomolecules 14:9910.3390/biom14010099 ↗
54. Demir Y, Türkeş C, Çavuş MS, Erdoğan M, Muğlu H, Yakan H, Beydemir Ş (2023) Enzyme inhibition, molecular docking, and density functional theory studies of new thiosemicarbazones incorporating the 4-hydroxy-3,5-dimethoxy benzaldehyde motif. Arch Pharm 356:220055410.1002/ardp.202200554 ↗
55. Demir Y (2019) The behaviour of some antihypertension drugs on human serum paraoxonase-1: an important protector enzyme against atherosclerosis. J Pharm Pharmacol 71:1576–158310.1111/jphp.13144 ↗
56. Boulton S, Selvaratnam R, Blondeau J-P, Lezoualch F, Melacini G (2018) Mechanism of selective enzyme inhibition through uncompetitive regulation of an allosteric agonist. J Am Chem Soc 140:9624–963710.1021/jacs.8b05044 ↗
57. Nagar S, Argikar UA, Tweedie D (eds) (2021) Enzyme kinetics in drug metabolism: fundamentals and applications. https://doi.org/10.1007/978-1-0716-1554-610.1007/978-1-0716-1554-6 ↗
58. Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V (2020) Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics 12:84610.3390/pharmaceutics12090846 ↗
59. Lamba D, Pesaresi A (2022) Kinetic modeling of time-dependent enzyme inhibition by pre-steady-state analysis of progress curves: the case study of the anti-Alzheimer’s drug galantamine. Int J Mol Sci 23:507210.3390/ijms23095072 ↗
60. Buker SM, Boriack-Sjodin PA, Copeland RA (2019) Enzyme–inhibitor interactions and a simple, rapid method for determining inhibition modality. Slas Discov: Adv Sci Drug Discov 24:515–52210.1177/2472555219829898 ↗
61. Voss L, Yilmaz K, Burkard L et al (2020) Impact of iron oxide nanoparticles on xenobiotic metabolism in HepaRG cells. Arch Toxicol 94:4023–403510.1007/s00204-020-02904-1 ↗
62. Ye M, Tang L, Luo M, Zhou J, Guo B, Liu Y, Chen B (2014) Size- and time-dependent alteration in metabolic activities of human hepatic cytochrome P450 isozymes by gold nanoparticles via microsomal coincubations. Nanoscale Res Lett 9:64210.1186/1556-276X-9-642 ↗
63. Choi K, Joo H (2019) Impact of gold nanoparticles on testosterone metabolism in human liver microsomes. Nanoscale Res Lett 14:20510.1186/s11671-019-3021-z ↗
64. Cornu R, Béduneau A, Martin H (2020) Influence of nanoparticles on liver tissue and hepatic functions: a review. Toxicology 430:15234410.1016/j.tox.2019.152344 ↗
65. Patel P, Kansara K, Senapati VA, Shanker R, Dhawan A, Kumar A (2016) Cell cycle dependent cellular uptake of zinc oxide nanoparticles in human epidermal cells. Mutagenesis 31:481–49010.1093/mutage/gew014 ↗
66. Hoshyar N, Gray S, Han H, Bao G (2016) The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 11:673–69210.2217/nnm.16.5 ↗
67. Yu J, Baek M, Chung H, Choi S-J (2011) Effects of physicochemical properties of zinc oxide nanoparticles on cellular uptake. J Phys: Conf Ser 304:012007
68. Preedia Babu E, Subastri A, Suyavaran A, Premkumar K, Sujatha V, Aristatile B, Alshammari GM, Dharuman V, Thirunavukkarasu C (2017) Size dependent uptake and hemolytic effect of zinc oxide nanoparticles on erythrocytes and biomedical potential of ZnO-ferulic acid conjugates. Sci Rep 7:420310.1038/s41598-017-04440-y ↗
69. Tang H-Q, Xu M, Rong Q, Jin R-W, Liu Q-J, Li Y-L (2016) The effect of ZnO nanoparticles on liver function in rats. Int J Nanomedicine 11:4275–428510.2147/IJN.S109031 ↗
70. Thermo Fisher Scientific (2012) Vivid™ CYP450 screening kits manual. Thermo Fisher Scientific. Retrieved from https://assets.thermofisher.com/TFS-Assets/LSG/manuals/Vivid_CYP450_Screening_Kits_man.pdf
71. Prasad AR, Basheer SM, Williams L, Joseph A (2019) Highly selective inhibition of α-glucosidase by green synthesised ZnO nanoparticles - in-vitro screening and in-silico docking studies. Int J Biol Macromol 139:712–71810.1016/j.ijbiomac.2019.08.033 ↗
72. Fu S, Yu F, Hu Z, Sun T (2022) Metabolism-mediated drug–drug interactions – study design, data analysis, and implications for in vitro evaluations. Med Drug Discov 14:10012110.1016/j.medidd.2022.100121 ↗
73. Prism - GraphPad. https://www.graphpad.com/features. Accessed 30 Mar 2024
74. Donato MT, Tolosa L, Gómez-Lechón MJ (2015) Culture and functional characterization of human hepatoma HepG2 cells. Methods Mol Biol 1250:77–9310.1007/978-1-4939-2074-7_5 ↗
75. Li K, Yu X-H, Maskey AR et al (2023) Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid. Front Pharmacol 13:104275610.3389/fphar.2022.1042756 ↗
76. Choi JM, Oh SJ, Lee SY, Im JH, Oh JM, Ryu CS, Kwak HC, Lee J-Y, Kang KW, Kim SK (2015) HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics. Arch Pharm Res 38:691–70410.1007/s12272-014-0502-6 ↗
77. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(research0034):1
78. Momma K, Izumi F (2011) VESTA 3 for three-dimensional visualization of crystal, volumetric and morphology data. J Appl Cryst 44:1272–127610.1107/S0021889811038970 ↗
79. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng Des Sel 8:127–13410.1093/protein/8.2.127 ↗
80. Chai MHH, Amir N, Yahya N, Saaid IM (2018) Characterization and colloidal stability of surface modified zinc oxide nanoparticle. J Phys: Conf Ser 1123:012007
81. Kim N-H, Jun Y-K, Cho G-B (2014) Se-loss-induced CIS thin films in RTA process after co-sputtering using CuSe2 and InSe2 targets. J Electr Eng Technol 9:1009–101510.5370/JEET.2014.9.3.1009 ↗
82. Barui S, Gerbaldo R, Garino N, Brescia R, Laviano F, Cauda V (2020) Facile chemical synthesis of doped ZnO nanocrystals exploiting oleic acid. Nanomaterials 10:115010.3390/nano10061150 ↗
83. Çalışkan B, Demir Y, Türkeş C (2022) Ophthalmic drugs: in vitro paraoxonase 1 inhibition and molecular docking studies. Biotechnol Appl Biochem 69:2273–228310.1002/bab.2284 ↗
84. Demir Y, Tokalı FS, Kalay E, Türkeş C, Tokalı P, Aslan ON, Şendil K, Beydemir Ş (2023) Synthesis and characterization of novel acyl hydrazones derived from vanillin as potential aldose reductase inhibitors. Mol Divers 27:1713–173310.1007/s11030-022-10526-1 ↗
85. Al Thaher Y, Chandrasekaran B, Jeeva S (2020) The importance of nano-materials characterization techniques. pp 19–37. https://doi.org/10.1007/978-3-030-36260-7_210.1007/978-3-030-36260-7_2 ↗
86. Raval N, Maheshwari R, Kalyane D, Youngren-Ortiz SR, Chougule MB, Tekade RK (2019) Importance of physicochemical characterization of nanoparticles in pharmaceutical product development. In: Basic fundamentals of drug delivery. Elsevier, pp 369–400. https://doi.org/10.1016/B978-0-12-817909-3.00010-810.1016/B978-0-12-817909-3.00010-8 ↗
87. Al-Khaial MQ, Chan SY, Abu-Zurayk RA, Alnairat N (2024) Biosynthesis and characterization of zinc oxide nanoparticles (ZnO-NPs) utilizing banana peel extract. Inorganics 12:12110.3390/inorganics12040121 ↗
88. Abdelbaky AS, Abd El-Mageed TA, Babalghith AO, Selim S, Mohamed AMHA (2022) Green synthesis and characterization of ZnO nanoparticles using Pelargonium odoratissimum (L.) aqueous leaf extract and their antioxidant, antibacterial and anti-inflammatory activities. Antioxidants (Basel) 11:144410.3390/antiox11081444 ↗
89. Abdelbaky AS, Mohamed AMHA, Sharaky M, Mohamed NA, Diab YM (2023) Green approach for the synthesis of ZnO nanoparticles using Cymbopogon citratus aqueous leaf extract: characterization and evaluation of their biological activities. Chem Biol Technol Agric 10:6310.1186/s40538-023-00432-5 ↗
90. Zeta Potential - Overview | Malvern Panalytical. https://www.malvernpanalytical.com/en/products/measurement-type/zeta-potential. Accessed 12 Oct 2024
91. Alyamani AA, Albukhaty S, Aloufi S, AlMalki FA, Al-Karagoly H, Sulaiman GM (2021) Green fabrication of zinc oxide nanoparticles using Phlomis leaf extract: characterization and in vitro evaluation of cytotoxicity and antibacterial properties. Molecules 26:614010.3390/molecules26206140 ↗
92. Huzaifaumar KD, Rizaner N (2018) Biosynthesis of zinc oxide nanoparticles using Albizia lebbeck stem bark, and evaluation of its antimicrobial, antioxidant, and cytotoxic activities on human breast cancer cell lines. Int J Nanomedicine 14:87–10010.2147/IJN.S186888 ↗
93. Zhao M, Ma J, Li M et al (2021) Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci 22:1280810.3390/ijms222312808 ↗
94. Lamb J, Hathaway L, Munger M, Raucy J, Franklin M (2010) Nanosilver particle effects on drug metabolism in vitro. Drug Metab Dispos: Biol Fate Chem 38:2246–225110.1124/dmd.110.035238 ↗
95. Kulthong K, Maniratanachote R, Kobayashi Y, Fukami T, Yokoi T (2012) Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity. Xenobiotica 42:854–86210.3109/00498254.2012.670312 ↗
96. Choi K, Riviere JE, Monteiro-Riviere NA (2017) Protein corona modulation of hepatocyte uptake and molecular mechanisms of gold nanoparticle toxicity. Nanotoxicology 11:64–7510.1080/17435390.2016.1264638 ↗
97. Imai S, Yoshioka Y, Morishita Y et al (2014) Size and surface modification of amorphous silica particles determine their effects on the activity of human CYP3A4 in vitro. Nanoscale Res Lett 9:65110.1186/1556-276X-9-651 ↗
98. Fröhlich E, Kueznik T, Samberger C, Roblegg E, Wrighton C, Pieber TR (2010) Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol 242:326–33210.1016/j.taap.2009.11.002 ↗
99. Wang S-H, Xia M, Wang Y, Lu Z, Peiwu G, Dai D, Zhou Y, Wu Q (2023) Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC-MS/MS. Thorac Cancer. https://doi.org/10.1111/1759-7714.1487010.1111/1759-7714.14870 ↗
100. Kaur S, Kaur K, Jindal J, Gill GK (2023) Characterization and inhibition kinetics of gut α-amylase from Chilo partellus through Lineweaver-Burk, fractional velocity and combination plots. Int J Trop Insect Sci 43:1987–200010.1007/s42690-023-01101-8 ↗